Results for 530 patients who recorded scores at baseline and Month 6 are shown in the
figure below.
Average change from baseline in E-RS: COPD score at Month 6
1
t
a
e
r
o 0.5
c s 86 95 87 91 85 86
D
P patients patients patients patients patients patients
O 0
C
:
S
R -0.76 -0.71
E- -0.5 -0.87
n -1.47
i e6
n ileh t n -1 -2.11 -1.93
o
s
aM
b
-1.5
m
o
r
f
e -2
g
n
a
h
c
e -2.5
g
a
r e Placebo Danirixin 5 mg Danirixin 10 mg
v
A
Danirixin 25 mg Danirixin 35 mg Danirixin 50 mg
Treatment Groups
The placebo group showed the largest decrease in the average change from baseline in
E-RS: COPD score. This means the placebo group showed a greater reduction of COPD
symptoms at month 6 compared with all the danirixin groups.
More information about the study results is available in the scientific results summaries
(links to those summaries are provided at the end of this document).
What were the side effects?
Unwanted medical events (adverse events) can happen to people when they receive a
medicine. Study doctors record these events. A summary of all these events can be